1/13/2014 9:13:26 AM
REDWOOD CITY, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a clinical-stage biopharmaceutical company, today provided a corporate update including new data on the modification of renin-angiotensin-aldosterone system inhibiting (RAASi) therapies from Part B of its two-part Phase 3 trial evaluating patiromer as a treatment for hyperkalemia; a new agreement with Lanxess to ensure the commercial manufacture and supply of the active ingredient of patiromer; and an update with respect to its senior management team. In addition, Relypsa confirmed that it is on track to submit a new drug application (NDA) for patiromer to the U.S. Food and Drug Administration (FDA) in the third quarter of this year, and expects to complete an approximately 20-patient Phase 1 onset-of-action study in the first half of this year.
Help employers find you! Check out all the jobs and post your resume.
comments powered by